Data sources

Explore the sources behind your research

Understand what each FDA dataset includes and how it supports your research, from product approvals and labeling to promotional enforcement.

FDA promotional enforcement letters

OPDP warning and untitled letters, plus relevant CBER untitled letters and archives, show promotional practices FDA challenged in specific circumstances.

Question it supports

Should we revise this claim, risk presentation, or campaign approach—or send it for closer MLR review?

Orange Book

Approved drug products and their regulatory context, including therapeutic-equivalence information.

Question it supports

Which approved products belong in our competitive landscape, and which warrant deeper investigation?

Purple Book

Licensed biologics, including biosimilar and interchangeable-product relationships.

Question it supports

Which biologic competitors should we monitor, and what is their regulatory relationship to the reference product?

National Drug Code Directory

Listed products, labelers, and product presentations made available through openFDA.

Question it supports

Which products and formulations belong on our watchlist, and which records refer to the product we are investigating?

DailyMed Structured Product Labels

Company-submitted labeling published by the National Library of Medicine.

Question it supports

What does the relevant label say about indications, populations, dosing, and safety—and what must reviewers verify before using a claim?

Klick RegLine™

RegLine preserves the value of the source material, then connects records using shared identifiers, aliases, and verified company relationships.

  • Normalize names
  • Resolve aliases
  • Respect distinct entities
  • Connect ownership history

One research-ready identity

Teva Pharmaceuticals USA

Recorded Watson, Actavis Generics, and Teva company names flow into Klick RegLine, which normalizes names, resolves aliases, preserves distinct entities, and connects verified ownership history for affected records to produce one research-ready company identity: Teva Pharmaceuticals USA.

Real-world case studies

See what entity resolution changes in real FDA records.

These examples are drawn from actual FDA records and RegLine’s current entity-resolution data—not fictional illustrations. Each shows what a name-only search could leave behind.

Real-world example · Fragmented names

NuCare: many variations, one company

NDC listing rows preserve many recorded variations of the NuCare name. RegLine connects them through shared labeler codes and resolves them to one company identity.

  • NUCARE PHARMCEUTICALS
  • NUCARE PHARAMCEUTICALS
  • NUCAREPHARMACEUTICALS
  • NuCare Pharmaceuticals, Inc.
What could be missed

A search for one spelling can return only part of the record. Resolution brings the distributed listing history into view without asking researchers to anticipate every variation.

Real-world example · False similarity

Merck & Co. and Merck KGaA: similar names, distinct companies

The harder task is sometimes refusing a merge. RegLine keeps these unrelated companies distinct at the entity level even though their names share a highly recognizable term.

  • MERCK & CO., INC.
  • MERCK KGAA
  • Two distinct company identities
What could go wrong

A name-similarity match can introduce false positives and blend unrelated regulatory histories. Entity-aware resolution protects the boundary between them.

Real-world example · Ownership history

Watson → Actavis Generics → Teva

Applicant records preserve multiple Watson name variations—including a name field that describes Watson as an indirect Teva subsidiary. Watson became Actavis in 2013; Teva later acquired the Actavis Generics business in 2016.

  • WATSON LABS INC
  • WATSON LABORATORIES INC FLORIDA
  • WATSON LABORATORIES INC AN INDIRECT WHOLLY OWNED SUB OF TEVA PHARMACEUTICALS USA INC
  • Affected records resolved under Teva Pharmaceuticals USA
What could be missed

A search limited to the current owner or one historical name can leave relevant earlier records behind. RegLine connects aliases and the verified ownership path for affected records so that history can be researched together without treating every Actavis record as part of the transaction.

Real-world example · Acquisition continuity

Juno → Celgene → Bristol Myers Squibb

Company histories continue through acquisitions and rebrands. RegLine consolidates Juno through Celgene and into Bristol Myers Squibb so searches can follow the relevant organization across each change.

  • Juno Therapeutics
  • Celgene
  • Bristol-Myers Squibb
  • One connected acquisition history
What could be missed

Research anchored only to today’s company name can overlook records published under earlier owners. Connected lineage makes those records discoverable as part of the same investigation.

Evidence for informed judgment.

Klick RegLine™ is an independent product of Klick Inc. It is not affiliated with or endorsed by the U.S. Food and Drug Administration. FDA data is foundational to life sciences research, and its depth reflects the scientific, regulatory, product, and company history it preserves. RegLine organizes that public record for research and monitoring while keeping the original sources in reach. Enforcement letters reflect FDA positions in specific circumstances at the time of publication. Review the original record, relevant labeling, and any later correspondence before drawing conclusions. RegLine does not provide definitive regulatory interpretations or guarantee compliance.